

00005.001280

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	Examiner: Not Yet Assigned
SHUNJI ICHIKAWA, ET AL.	)	Group Art Unit: 1614
Application No.: 10/560,598	)	
Filed: December 13, 2005	)	
For: ANTIEPILEPTIC AGENTS	)	June 22, 2006

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUBMISSION OF MISCELLANEOUS PCT FORMS


Sir:

Enclosed to complete the record and for the Examiner's convenience is Form PCT/IB/338, an English translation of the International Preliminary Report on Patentability (Form PCT/IB/373) and the Written Opinion of the International Searching Authority (Form PCT/ISA/237) in the above-identified application. The references discussed in the Written Opinion are all cited in Applicants' June 21, 2006 Information Disclosure Statement being filed currently herewith.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,



Lawrence S. Perry  
Attorney for Applicants  
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200


LSP\ac

NY\_Main 576481\_1

IFW

00005.001280

PATENT APPLICATION



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
SHUNJI ICHIKAWA, ET AL.  
Application No.: 10/560,598  
Filed: December 13, 2005  
For: ANTIEPILEPTIC AGENTS

)      Examiner: Not Yet Assigned  
      )      Group Art Unit: 1614  
      )  
      )  
      )      June 22, 2006

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed documents are also enclosed.


All the documents were cited in the International Search Report, a copy of which is enclosed as well. For the Examiner's convenience, Reference A is cited as an English-language equivalent of Reference B.

## CONCLUSION

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.


Respectfully submitted,



Lawrence S. Perry  
Attorney for Applicants  
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3800  
Facsimile: (212) 218-2200

LSP\ac

ATTY DOCKET NO.  
00005.001280APPLICATION NO.  
10/560,598APPLICANT  
**SHUNJI ICHIKAWA, ET AL.**FILING DATE  
**December 13, 2005**GROUP  
**1614**

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A	5,756,735	5/98	Suzuki, et al.	544	267	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
	B	WO 92/06976	4/92	PCT			Abstract

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

C	Clitgaard, et al., "Contrasting effects of adenosine A <sub>1</sub> and A <sub>2</sub> receptor ligands in different chemoconvulsive rodent models", <i>European Journal of Pharmacology</i> , Vol. 242, No. 3 (1993), pages 221-228
D	De Sarro, et al., "Effects of adenosine receptor agonist and antagonists on audiogenic seizure-sensible DBA/2 mice", <i>European Journal of Pharmacology</i> , Vol. 371, No. 2/3 (1999), pages 137-145

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.